Zimmer Biomet Posts $2.06B in Third-Quarter Sales
ZBH sits 22% above its 52-week low of $79.12.
Summary
Zimmer Biomet reported third-quarter net sales of $2.063 billion, up 3.7% constant currency, with adjusted EPS of $1.90 and net income of $191.6M. The company raised its 2026 adjusted EPS view to $8.50-$8.60, up from its prior $8.47-$8.59 range, and raised 2026 organic constant-currency revenue growth guidance to 3.0%-3.5%. The quarter lands after a leadership restructuring disclosed in the September 8 8-K, which promoted Gary Campbell, Brian Hatcher and others effective October 1. The company has been buying back stock under its existing $1.5B authorization, and Q1 2026 results were described as strong with a tariff refund boosting earnings.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Zimmer Biomet raised 2026 organic constant-currency revenue growth guidance to 3.0%-3.5% and reported Q3 net sales of $2.063 billion, up 3.7% constant currency.
At the time of this announcement, ZBH was trading at $96.80 on NYSE in the Life Sciences sector, with a market capitalization of approximately $18.5B. The 52-week trading range was $79.12 to $103.70. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.